MedExecWomen Invites Women in Life Sciences to Join the 2021 Annual Conference in Boston in October

MedExecWomen, a non-profit organization focused on empowering female executives to accelerate the positive impact of medical devices, diagnostics, drug delivery, and digital healthcare around the world, is hosting the second MedExecWomen Annual Conference for women in the life sciences industry later this month in Boston. This year’s conference will be in person on Oct. 26, 2021, at the Sheraton Boston in Back Bay and registration is now open.

The upcoming conference, Medical Innovation in a Post-Covid World, will be a one-day meeting featuring expert panelists — some of the top physicians and leaders in the life science and medical device industries — discussing the state of the market and several of the biggest ongoing industry challenges and how to overcome them, including:

  • Analyst opinions on the state of the medtech sector
  • COVID changes for how medtech companies lead global organizations and expand commercial operations
  • Where inpatient procedures are going
  • Inequities in healthcare spanning clinical trial participation, patient education and hesitancy, healthcare delivery, and access
  • How to become a board member
  • Ongoing innovation in digital health technologies
  • Healthcare financial pressure due to COVID and ongoing hospital operational practices

“You’ll be joining as many as 150 executive life science women to dig deeper into these important topics and have conversations with experts across the industry,” said Co-founder of MedExecWomen and President and Founder of Medi-Vantage, Maria Shepherd. “There are so many challenges now and into 2022, and we expect even more change in this new normal. In Boston, our medtech expert panelists are going to provide some real insight into what they foresee.”

Full COVID precautions, including masking, ensuring that all registrants are fully vaccinated, and social distancing are being taken to ensure your safety at this important meeting.

Interested in attending? Registration is open at:

A full agenda is available at:


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy